140 related articles for article (PubMed ID: 24597490)
1. Prospects for MEK inhibitors for treating cancer.
Martin-Liberal J; Lagares-Tena L; Larkin J
Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
3. Trametinib (GSK1120212) in the treatment of melanoma.
Salama AK; Kim KB
Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
[TBL] [Abstract][Full Text] [Related]
4. The role of MEK inhibitors in the treatment of metastatic melanoma.
Grimaldi AM; Simeone E; Ascierto PA
Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
[TBL] [Abstract][Full Text] [Related]
5. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
[TBL] [Abstract][Full Text] [Related]
6. Trametinib.
Zeiser R
Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
[TBL] [Abstract][Full Text] [Related]
7. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibition in BRAF-mutated melanoma.
MacKenzie A; Boycott K
N Engl J Med; 2012 Oct; 367(14):1364-5. PubMed ID: 23034029
[No Abstract] [Full Text] [Related]
9. MEK inhibition in BRAF-mutated melanoma.
Ascierto PA
N Engl J Med; 2012 Oct; 367(14):1364; author reply 1365. PubMed ID: 23034028
[No Abstract] [Full Text] [Related]
10. Promises from trametinib in RAF active tumors.
Sausville EA
N Engl J Med; 2012 Jul; 367(2):171-2. PubMed ID: 22663012
[No Abstract] [Full Text] [Related]
11. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
Seghers AC; Wilgenhof S; Lebbé C; Neyns B
Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
[TBL] [Abstract][Full Text] [Related]
12. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
Ho MY; Morris MJ; Pirhalla JL; Bauman JW; Pendry CB; Orford KW; Morrison RA; Cox DS
Xenobiotica; 2014 Apr; 44(4):352-68. PubMed ID: 23971497
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
Patel U; Cornelius L; Anadkat MJ
JAMA Dermatol; 2015 Jan; 151(1):78-81. PubMed ID: 25426865
[TBL] [Abstract][Full Text] [Related]
15. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
Lian T; Li C; Wang H
Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
[TBL] [Abstract][Full Text] [Related]
16. Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS; Miner JN
Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
[TBL] [Abstract][Full Text] [Related]
17. Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors.
Reinhard R; Gebhardt C; Schmieder A; Umansky V; Utikal J
J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e375-e377. PubMed ID: 28222227
[No Abstract] [Full Text] [Related]
18. A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
[TBL] [Abstract][Full Text] [Related]
19. Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case.
Giraud V; Longvert C; Houlle-Crepin S; Danel C; Labrune S; Camus P; Saiag P; Chinet T
BMC Cancer; 2015 Oct; 15():732. PubMed ID: 26481107
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
Boull C; Hook K; Moertel C; Maguiness S
Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
